CD19 and acute lymphoblastic leukemia: By large-scale production of clinical-grade CD19-redirected CAR Tscm cells, Sabatino et al., reported that CAR–modified CD8+ Tscm cells mediate robust and long-lasting antitumor responses against systemic ALL xenografts and exhibit improved metabolic fitness compared to conventional CD8+ CAR T cells generated with standard clinical protocols (150).